



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 7/48</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 98/47466</b> <b>(43) International Publication Date:</b> 29 October 1998 (29.10.98)
<b>(21) International Application Number:</b> PCT/EP98/02159 <b>(22) International Filing Date:</b> 14 April 1998 (14.04.98)  <b>(30) Priority Data:</b> MI97A000928 18 April 1997 (18.04.97) IT  <b>(71) Applicant (for all designated States except US):</b> I.V. PHARMA S.A.S. [IT/IT]; Via Brié, 9/C, I-10090 Romano Canavese (IT).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> IZZO, Marcello [IT/IT]; Via Circumvallazione, 19, I-80030 San Paolo Belsito (IT). VERZELLA, Gianfranco [IT/IT]; Via Brié, 9/C, I-10090 Romano Canavese (IT).  <b>(74) Agent:</b> SPADARO, Marco; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).	<b>(81) Designated States:</b> BR, CA, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>  <b>(88) Date of publication of the international search report:</b> 11 February 1999 (11.02.99)	

**(54) Title:** THE USE OF THIOLYGLIC ACID AS DEPIGMENTING AGENT**(57) Abstract**

The present invention relates to the use of 2-mercaptoacetic acid (thioglycolic acid) for the preparation of cosmetic and pharmaceutical compositions having depigmenting activity on epidermal spots of ferric origin (haemosiderin), which often occur during sclerotherapy or intravenous infusion administrations. Thioglycolic acid is also useful as antiaging agent.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/02159

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K7/48

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 34280 A (PROCTER & GAMBLE) 21 December 1995 see page 4, line 23-26 see claim 1 --- -/-	1-10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

Date of the actual completion of the international search

12 November 1998

Date of mailing of the international search report

03.12.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Sierra Gonzalez, M

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/02159

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE WPI  Week 8401  Derwent Publications Ltd., London, GB;  AN 84-002869  XP002077094  "Skin bleaching composition for treating skin diseases, freckles, etc.-contains cod-liver oil, sulphur compound, hydrogen peroxide salicylic acid and acidic bromate"  A  see abstract  &amp; JP 58 198421 A (KOSAKA R)  18 November 1983</p>	1-10
X	<p>US 4 195 095 A (SHEFFNER AARON L)  25 March 1980  see the whole document</p>	6-9
X	<p>DATABASE WPI  Week 8210  Derwent Publications Ltd., London, GB;  AN 82-18405e  XP002084155  "Cosmetic for hair conditioning and preventing skin ageing-comprises sulphur-containing reducing agent, e.g. thioglycolic acid or cysteine or ascorbic acid and cop. obtd. by oxidising reducing agent"  A  see abstract  &amp; JP 57 016810 A (MURAI Y) 28 January 1982</p>	6-9,11
X	<p>WO 91 02538 A (MORRIS JOHN CO INC)  7 March 1991  see claims 1,5,43,48,52</p>	6-9,11

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 98/02159

## B x I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

**1. Claims: 1-10**

Cosmetic and pharmaceutical composition containing  
2-mercaptoacetic acid. Use thereof as depigmenting agent.

**2. Claim : 11**

Use of 2-mercaptoacetic acid as antiageing agent.

### Information on patent family members

PCT/EP 98/02159

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9534280 A	21-12-1995	AU 2901995 A CA 2192665 A CN 1152865 A CZ 9603659 A EP 0758882 A JP 10501817 T	05-01-1996 21-12-1995 25-06-1997 15-10-1997 26-02-1997 17-02-1998
US 4195095 A	25-03-1980	US 4107330 A	15-08-1978
WO 9102538 A	07-03-1991	AU 6425590 A CA 2065044 A EP 0487648 A JP 5503071 T	03-04-1991 19-02-1991 03-06-1992 27-05-1993

**THIS PAGE IS  
INTENTIONALLY  
BLANK**





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 7/00</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 98/47466</b> <b>(43) International Publication Date:</b> 29 October 1998 (29.10.98)
<b>(21) International Application Number:</b> PCT/EP98/02159 <b>(22) International Filing Date:</b> 14 April 1998 (14.04.98)  <b>(30) Priority Data:</b> MI97A000928      18 April 1997 (18.04.97)      IT  <b>(71) Applicant (for all designated States except US):</b> I.V. PHARMA S.A.S. [IT/IT]; Via Brié, 9/C, I-10090 Romano Canavese (IT).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> IZZO, Marcello [IT/IT]; Via Circumvallazione, 19, I-80030 San Paolo Belsito (IT). VERZELLA, Gianfranco [IT/IT]; Via Brié, 9/C, I-10090 Romano Canavese (IT).  <b>(74) Agent:</b> SPADARO, Marco; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).		<b>(81) Designated States:</b> BR, CA, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> THE USE OF THIOGLYCOLIC ACID AS DEPIGMENTING AGENT  <b>(57) Abstract</b>  The present invention relates to the use of 2-mercaptoacetic acid (thioglycolic acid) for the preparation of cosmetic and pharmaceutical compositions having depigmenting activity on epidermal spots of ferric origin (haemosiderin), which often occur during sclerotherapy or intravenous infusion administrations. Thioglycolic acid is also useful as antiaging agent.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

THE USE OF THIOGLYCOLIC ACID AS DEPIGMENTING AGENT

The present invention relates to the use of 2-mercaptoacetic acid (thioglycolic acid) for the preparation of cosmetic and pharmaceutical compositions having depigmenting activity on skin spots of ferric origin (hemosiderin), which often occur during sclerotherapy or intravenous infusion administrations. Such spots are present on skin as more or less permanent pigmentations.

Background of the invention

The formation of hemosiderinic (ferric) pigmentations on the treated site is a side effect given by all the sclerosing solutions, normally used in therapy. This side effect is quite general and independent from the correct use of sclerosing solutions and the technique of application of sclerotherapy. Hemosiderinic pigmentations appear in the form of dark cutaneous spots, which are felt as a serious aesthetic damage by patients, who consequently do not normally comply with this kind of therapy. These inconveniences are more frequent in small blood vessels, such as telangiectasis, which notoriously represent 80% of sclerotherapeutic applications. According to some Authors (M.P. Goldman, USA), the incidence of these post-sclerosis hyperpigmentation is estimated about 10-30 % of the patients undergoing sclerosing therapy independently from the type of medicament used.

Most of all, prevention of hyperpigmentation is obtained by applying a correct sclerotherapeutic technique, by selecting the appropriate type and doses

of sclerosing agent. However, notwithstanding the above measures, these side effects may happen even to the most expert sclerotherapist.

Accordingly, the availability of a cosmetic or pharmaceutical agent capable of eliminating or at least reducing this aesthetic damage is still today strongly desired by the therapist and patients.

Among the several preparations having depigmenting activity, the so-called hemosiderinic solubilizing agents, for topical use, have proven to be effective and do not show undesirable side effects. These are preparations normally of cosmetic adjuvants able to "solubilize" hemosiderin.

Post-sclerotherapy pigmentations form in about 6-12 weeks from the end of therapy; they have a linear-macular morphology with a grey to dark brown colour.

Generally, colouring tends to brown in the course of some years, except in case of spontaneous resolutions.

A number of scientific proposals has been offered to explain the genesis of these pigmentations, but only in the last 20 years, experimental evidences of their exact nature have been obtained, thanks to bioptic studies of some Authors (Barner, 1977; Cuttel and Fox, 1982; Goldman, 1987) who demonstrated the almost exclusively haematic origin of the pigment associable with the protein complex called "hemosiderin".

In particular, Goldman (J. Dermatol. Surg. Oncol., 13,547.1987) studied the effect of the pigmentation genesis in patients subjected to telangectasic therapies (small blood vessels) using different agents in

different conditions.

The essentially "haematic" nature of the "post-sclerotic" pigmentation was therefore widely demonstrated.

5           Hemosiderin, which is a base component of pigmentation, forms from the degradation of haeme in the cycle of bile genesis, and has different morphologies of complex nature, as shown by some studies (Richter, 1957 e 1965; Shoden, 1960; Wells, 1962). Genesis cycle, 10 during sclerosing therapies, can be summarized as follows:

- sclerosing action determines erythrodiapedesis, due to the combined effect of needle shock and alteration of blood vessel permeability: hence the 15 subsequent degradation of haemoglobin in the tissue-site;
- consequently, there is complexation with apoferritin part of the iron released from haeme and formation of the ferritin protein complex, 20 which represents the mobile and hydrosoluble pool of ferric storage in physiological environment;
- the subsequent degradation to hemosiderin, which is insoluble in aqueous environments, can be explained by the action of acid environment (often given by 25 sclerosing solutions themselves, which have acidic pH) and a further degradation of ferritin and loss of the protein part apoferritin. The hemosiderin complex is water-insoluble, except at very low pH, thus allowing the organism to have available an 30 "iron pool", which is released only in particular pH conditions.

Therefore hemosiderin would be a sort of biological advantage, because, on one hand, it would release iron only in particular conditions ( $\text{pH} < 4.5$ ) as shown by O'Connel (1986, Biochem. J., 234:727-731) and, on the other hand, it would avoid the presence of free iron, which is known to be toxic.

Taking into account what above discussed, in the topical treatment of epidermal spots, one should distinguish the goal of reducing and eliminating pigmentations of melanine origin, which earlier patents relates to (South Africa patent n. 68-3773), with respect to the goal of reducing and eliminating pigmentations of haematic origin, in particular those of hemosiderinic genesis and coming from sclerotherapy and intravenous infusion treatments (blood transfusions, etc.). Reduction and elimination of skin pigmentations of haematic origin, in particular those of hemosiderinic genesis and coming from sclerotherapy and intravenous infusion treatments (blood transfusions, etc.) is the problem faced by the present invention.

As above said, contrary to ferritin, the protein complex containing trivalent iron is insoluble and accumulates in dermis permanently (particularly in papillar dermis) showing a characteristic brown spot, with remarkable unesthetic effect.

In previous years, a number of techniques, believed to be suitable to solve such essentially unaesthetic inconvenience, were proposed.

As a matter of clarity and better understanding, these techniques may be classified in instrumental techniques and in techniques using substances having

physico-chemical activities.

Main instrumental techniques are the following :

1. Cryotherapy: it is a complex and expensive technique, which has the intrinsic difficulty of determining the exact deepness of frozing.
2. Dermo-Microabrasion: consists in the use of vacuum systems with mineral powders (Corundum). It gives variable results and is expensive.
3. Laser systems: two expensive kinds of apparatuses are available, but variable and not reproducible results are obtained.

Chemical substances having depigmenting activity can be divided in two classes:

1. Substances having chelating action on hemosiderin iron;
2. Substances having solubilizing action on hemosiderin.

Both classes are used in topical formulations.

In the first class ethylenediaminetetracetic acid (EDTA) is found; it shows the well-known chelating effect on metals and is used in formulations having 15% concentration (150 mg/ml).

Further, desferroxamine is a hydrosoluble sideramine capable of chelating iron ion specifically. It is used topically, but the results are not reproducible.

Among the solubilizing substances of the second class, the following are mentioned:

- alfa-hydroxyacids, in particular 2-hydroxyacetic acid (glycolic acid). This substance does not have a constant effect in its results because it is not

6

capable of reaching the derm and, in order to obtain a medium effect, it requires the application on epidermis for very long times.

5 Plurihalogen acids. In particular trichloroacetic acid is mentioned, because it has a very good penetration capability in the cutis and can easily reach hemosiderin and solubilize it, due to its characteristics of very strong acid. But occurrence of side effects, such as hypopigmentations and post-phlogosis scars from chemical burning are reported. Also incidents of activation of keratocytes of the basal layer and reduction of the basal melanophores are reported. Normally, trichloroacetic acid is used in aqueous or  
10 amphiphilic solutions, with concentrations ranging from 10 to 40%.

Examining in detail the simplest and less expensive techniques, which are those using cosmetic or pharmaceutical formulations having a solubilizing  
20 action, the person having ordinary experience in the art will ascertain some drawbacks that, in one way or in another, lower the efficacy or makes their use difficult. In fact, taking into account what above stated, it can be said:

- 25 - the use of formulations containing chelating agents, such as EDTA or desferroxamine (already proposed by some authors, see Meyers in 1966 and Goldman in 1992) give variable, uncertain results, likely due to their difficult diffusion through  
30 cutis, since topical way is the most preferred;
- the selection of solubilizing substances unfortu-



nately comprises other kinds of problems. Trichloroacetic acid, although highly effective, is dangerous because it is a strong acid and has a strong protein denaturing activity: even if it used at low concentrations or for short periods of time (but in this case efficacy is lowered), it gives rise to phlyctena, hypopigmentations due to melanocyte destruction. On the contrary, the choice of using preparations containing glycolic acid does not show these noxious effects, since it is not a strong acid, as trichloroacetic acid is, but it has a very superficial activity, as it cannot easily penetrate the epidermic-dermal junction: in order to reach the minimum efficacy, very long application times are necessary. But in this case, side effects similar to those experienced with trichloroacetic acid occur, for example hypopigmentation. Accordingly, a correct and cautious use gives only variable results.

For the reasons above discussed, the therapist is still looking for a highly effective active ingredient without exposing the patient to the risks or problems encountered in the present state of the art.

#### Summary of the invention

It has now surprisingly been found that 2-mercaptoacetic acid (commonly named "thioglycolic acid") shows a strong and exceptional depigmenting activity and gives constant results. Advantageously, many side effects, arising from the use of the active ingredients of the art, do not appear when 2-mercaptoacetic acid is used.

Accordingly, it is an object of the present invention the use of 2-mercaptoacetic acid as active ingredient for the preparation of a cosmetic and pharmaceutical composition having depigmenting activity on skin spots of ferric origin.

It is another object of the present invention, a method for the cosmetic treatment of depigmentation of skin spots of ferric origin comprising the application on epidermis of a composition containing 2-mercaptoacetic acid.

The inventors do not wish to be bound to any theory, however they believe that the strong solubilizing activity at dermis level with respect to hemosiderin iron is due not only to the acidic characteristic of the active ingredient, but, above all, to the presence of -SH group, which gives the molecule a strong affinity for iron ion in the skin: then, according to the present invention, there is the advantageous result to achieve both the solubilizing effect and the complexing effect with a single active ingredient.

The present invention offers the art of sclerotherapy a number of advantages, because, other than a well established and constant efficacy, the composition is endowed with a high safety of use.

- Only very short application times are required, at most a few minutes, and it is subsequently eliminated with washing and neutralization with a buffer or simply by washing the treated site with tap water. Short application times allow to eliminate risks and dangers of harmful effects, such as

erythemas, phlyctena, hypopigmentations, etc.

- It has also been found that the strong affinity for iron ion of 2-mercaptoacetic acid gives it a behaviour similar to that of apoferritin, therefore it can bind to hemosiderin even at low concentrations, thus giving higher efficacy at concentrations lower than those of glycolic acid (used at 7%) and trichloroacetic acid (used at 20-40%).

It has further surprisingly been found that thioglycolic acid gives cutis a "rejuvenating" effect. Therefore, it is another object of the present invention the use of 2-mercaptoacetic acid for the preparation of a cosmetic composition having antiageing activity. Also a cosmetic treatment of skin ageing is within the scope of the present invention.

Once again, the inventors do not wish to base the invention on any theory, but also in this case, the antiageing effect might be explained by the easy grade of oxidation of 2-mercaptoacetic acid, then it is likely that it interacts with free radicals.

2-mercaptoacetic acid was used as chemical reagent in laboratory for the determination of hemosiderin and characterization of its structure and chemical composition (Shoden and Sturgeon in Hemosiderin; Acta Hematol., 376-392, 1960).

Other Authors showed the capability of 2-mercaptoacetic acid of eliminating iron accumulations from spleen and to have antioxidant activity (due to -SH group), for example demonstrated by its presence of metabolite of carboxymethylcysteine. (Joo et al., Biol. Met. 3(34), 1715, 1990; Hofman et al., Drug.

Metab. Dispos., 19(1)22-6, Jan-Feb. 1991).

Efficacy of 2-mercaptoacetic acid is due only to its characteristic of being simply an acid: in fact it has an acidity definitely lower than the one of trichloroacetic acid (a well known depigmenting agent) (see Table 1 below), in fact 2-mercaptoacetic acid is a mid-strength acid, such as glycolic acid, and as the latter, slightly stronger than acetic acid.

Therefore, the present invention provides an active ingredient, which, although highly effective, does not give side effects. Topical use of the compositions containing 2-mercaptoacetic acid, according to the present invention, does not cause burning or erythema except rare cases, but of very low intensity; also sensitization is quite exceptional and temporary.

Table 1 - Acidic strength

<u>Substance</u>	<u>Chemical formula</u>	<u>pKa value</u>
Acetic acid	$\text{CH}_3\text{COOH}$	4.76
Glycolic acid	$\text{HO}-\text{CH}_2\text{COOH}$	3.83
20 Tioglycolic acid	$\text{HS}-\text{CH}_2\text{COOH}$	3.68
Chloroacetic acid	$\text{Cl}-\text{CH}_2\text{COOH}$	2.85
Trichloroacetic acid	$\text{Cl}_3\text{CCOOH}$	0.70

Pharmaceutical and cosmetic compositions containing 2-mercaptoacetic acid as active ingredient are a further object of the present invention. Said compositions fulfill the scope to provide the phlebologist suitable means for an effective cosmetic or therapeutic treatment without contra-indications with the scope of eliminating or at least minimizing side effects of hemosiderinic pigmentations during sclerotherapy treatments.

According to the present invention, 2-mercaptoace-

tic acid shall be used in an amount higher than the minimum value of 3% by weight, thus providing a very effective therapeutical means, that in any case is to be used in a treatment in casualty department.

5           Compositions having definitely lower concentrations (lower than 3% by weight), are foreseen for a possible continuation of the treatment at home, in order to establish an effective maintenance treatment.

10           Generally, the effective amount of active ingredient is comprised from 0.5 to 30% by weight. This range of concentration is also useful to be used as an antiaging tool.

15           According to the present invention, the cosmetic composition containing 2-mercaptoacetic acid shall have a pH of the aqueous base ranging from 2.5-7.0, by adjusting the aqueous solution either with basic agents (sodium, ammonium or potassium hydroxide solution) or with mixtures of suitable buffer salts (sodium or potassium phosphate salts).

20           The compositions according to the present invention are preferably in the form of hydro-alcoholic solutions or gels or ointments.

25           The preparation of the compositions can be carried out according to conventional techniques well-known to the skilled person.

          As an example, methods for industrial manufacture are disclosed below:

- 30           1. Solutions having concentrations comprised in the 0.5-15% w/w range in 20 ml bottle and/or 2 ml ampoules.
2. Ointments and/or gels having concentrations compri-

12

sed in the range 0.5-15% w/w in 20 g tube and/or 3 g sachets.

Example 1

Formulation for the preparation of 1000 g of 12% solution, in 20 ml bottles and/or 2 ml ampoules.

<u>Starting materials</u>		<u>Amounts gram/Kg</u>
		<u>12% solution</u>
	Thioglycolic acid 100%	120
	Ethyl alcohol 96°	200
10	Polyethylene glycol 400	200
	Antioxidant	1.00
	Perfume	20
	Water : q.s. to	1000 grams.

In a glass vessel, equipped with stirrer, ethyl alcohol is mixed with polyethylene glycol till complete dissolution; antioxidant, then thioglycolic acid and perfume are slowly added while stirring.

Depurated water is added under stirring to the final weight in order to have a complete dissolution.

The mass is filtered, if necessary, through membrane and used for primary packaging by means of an equipment with automatic control of the distributed quantity.

Moulded glass bottles, having brown colour for light protection, are used.

Class I-glass ampoules are packaged in normal conditions, since the solutions are not for injection: ampoule filling is carried out in nitrogen atmosphere, having previously purged the ampoules with nitrogen, to preserve the best stability during the time.

Example 2

Formulation for the preparation of 100 grams 12 % of ointment and/or gel in 20 g tube and/or in 3 g sachets.

5	<u>Starting materials</u>	<u>Amount in grams for 12% ointment/gel</u>	<u>Component characteristics</u>
	Mercaptoace-		
	tic acid	12.0	Aqueous phase
	Glycerine	4.0	Aqueous phase
10	Xanthan Gum	2.0	Aqueous phase
	Brij 721/72	5	Emulsifying
	Cetyl/stearyl		
	alcohol	3.0	Fatty phase
	Cetiol V	4	Fatty phase
15	Isopropyl		
	myristate	3.0	Fatty phase
	Titanium dioxide	2.0	Solid phase
	Tocopheryl		
	acetate	1	Antioxidant
20	Perfume	0.2	Hydroalcohol-
			lic Phase
	Preserved water	q.s. to 100 grams	Aqueous phase

Fatty phase: All the fatty materials are placed in a suitable vessel and melted at the temperature of 60-70°C, keeping the mass under stirring.

While stirring, emulsifying agent (Brij), tocopheryl acetate and titanium dioxide are added to the molten mass; subsequently, temperature is lowered to about 50°C.

Aqueous phase: In a similar manner and into a second

14

suitable vessel, glycerine and the active ingredient (mercaptoacetic acid) are dissolved in water keeping the mixture under continuous stirring, until complete dissolution. Perfume is added, then the mass is warmed to about 50°C.

5

The aqueous phase is subsequently percolated into the fatty phase, kept under stirring with the usual technique for the preparation of oil/water emulsions, cooled down to a temperature such that to maintain the fluidity necessary for the subsequent filling phase in the primary packaging, which can consist of tubes (plastic or metal) or sachets of polycoupled material.

10



CLAIMS

1. The use of 2-mercaptoacetic acid as active ingredient for the preparation of a cosmetic and pharmaceutical composition having depigmenting activity on skin spots of ferric origin.
2. The use of 2-mercaptoacetic acid as active ingredient for the preparation of a medicament having depigmenting activity on skin spots of ferric origin.
3. The use according to claim 1 or 2, wherein the amount of active ingredient is comprised between 0.5 and 30% by weight.
4. The use according to claim 1 or 2, wherein the amount of active ingredient is at least 3% by weight.
5. The use according to claim 1 or 2, wherein the amount of active ingredient is less than 3% by weight.
6. Cosmetic and pharmaceutical composition containing 2-mercaptoacetic acid as active ingredient in admixture with conventional vehicles and excipients.
7. Cosmetic and pharmaceutical composition according to claim 6, wherein the active ingredient is contained in an amount comprised between 0.5 and 30% by weight.
8. Cosmetic and pharmaceutical composition according to claim 7, wherein the active ingredient is contained in an amount of at least 3% by weight.
9. Cosmetic and pharmaceutical composition according to claim 7, wherein the active ingredient is contained in an amount less than 3% by weight.
10. A method for the cosmetic treatment of epidermal spots of ferric origin comprising the application on epidermis of a composition of claims 6-9.

16

11. A method for the cosmetic treatment of skin ageing comprising the application on epidermis of a composition of claims 6-9.